News
Market and company headlines
BIAFAll
Loading
04:00-09:00Oct 132 Stories
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
SAN ANTONIO, October 13, 2026--bioAffinity Technologies to present positive data on new test under development to measure lung inflammation in asthma and COPD at CHEST 2026
bioAffinity Technologies To Present New Data On Sputum-Based Tests In Development To Characterize Lung Inflammation And Detect Multiple Protein Biomarkers Of Lung Inflammation At CHEST 2026
Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targetsCompany advances research and development in diagnostic tests for major lung diseases
11:00-13:00Oct 92 Stories
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, has closed its previously announced registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) with an institutional investor at a purchase price of $6.122 (or $6.115 per p
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
SAN ANTONIO, October 09, 2026--BIAF announces closing of $4 million registered direct financing of common stock and private placement priced at-the-market under Nasdaq rules
12:00-14:00Oct 82 Stories
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, has entered into a definitive agreement with an institutional investor to sell shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $6.122 (or $6.115 per pre-funded warrant)
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
SAN ANTONIO, Texas, October 08, 2026--BIAF Announces $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
10:00Oct 81 Story
04:00-09:00Sep 302 Stories
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
SAN ANTONIO, September 30, 2026--bioAffinity and AvMEDICAL jointly presented CyPath Lung for the first time under their new distribution agreement at NAVREF 2026 Annual Conference.
bioAffinity Technologies, AvMEDICAL Deliver First Joint Exhibition Of CyPath Lung
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, is taking significant steps toward
05:00Sep 281 Story
08:00-11:00Sep 222 Stories
bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans’ Research Conference
bioAffinity Technologies (NASDAQ:BIAF) will present new clinical findings on its noninvasive lung cancer test, CyPath® Lung, at the 2026 NAVREF Annual Conference, running September 27–30 in Arlington, Virginia. The company is set to unveil two posters focused on the test’s use in veteran and military healthcare settings.
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
SAN ANTONIO, September 22, 2026--bioAffinity Technologies will present two posters related to the CyPath Lung diagnostic test for lung cancer at the 2026 NAVREF Annual Conference.
04:00Sep 221 Story
11:00-18:00Sep 172 Stories
These stocks are moving in today's after hours session
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant
Shares of BioAffinity Technologies are surging Thursday after securing a key Hong Kong patent for its CyPath Lung diagnostic.
08:00-11:00Sep 172 Stories
bioAffinity Technologies Secures Hong Kong Patent for CyPath Lung Cancer Diagnostic
The new patent extends intellectual property protection for the company’s noninvasive lung cancer detection technology in Asia, complementing its existing Chinese patent. Key Investor TakeawaysbioAffinity Technologies (NASDAQ:BIAF) has received a Hong Kong patent covering core technology used in its CyPath Lung diagnostic test.
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
SAN ANTONIO, September 17, 2026--bioAffinity announces new Hong Kong patent that protects the proprietary technology behind its noninvasive CyPath Lung diagnostic for lung cancer.
04:00Sep 171 Story
02:00Sep 51 Story
04:00-16:00Sep 42 Stories
Which stocks are experiencing notable movement on Friday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Immuron (NASDAQ:IMRN) stock increased by 64.9% to $1.83 during Friday's pre-market session. The company's market cap stands at $8.9 million. Akanda (NASDAQ:AKAN) shares increased by 27.52% to $4.68.
16:00Sep 31 Story
04:00Aug 201 Story
04:00Aug 191 Story
08:00-11:00Aug 182 Stories
Tuesday's session: gap up and gap down stocks
Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.
Top movers in Tuesday's pre-market session
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
04:00Aug 182 Stories
bioAffinity Enters Into Distribution Agreement With AvMEDICAL Expanding bioAffinity's Commercial Reach Through AvMEDICAL's Existing Sales Team
New partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwideAgreement significantly expands bioAffinity's commercial reach through
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Amylyx Pharmaceuticals (NASDAQ:AMLX) stock increased by 27.5% to $27.32 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.3 billion. bioAffinity Technologies